LUMINA 2 rilzabrutinib study in warm autoimmune hemolytic anemia

Phase 2, open-label, single-arm trial of rilzabrutinib in warm autoimmune hemolytic anemia (wAIHA), sponsored by Sanofi. Primary endpoints: Proportion of participants with overall hemoglobin response and Proportion of participants who maintain durable response achieved during Part A or achieve a durable response during Part B and have a hemoglobin response. Planned start Jan 2022; status: authorised.